The Albumin study (ALB-TRIAL) is starting.
We are excited to announce that we are about to start a new research project. ALB-TRIAL is a new international study which is part of the MICROB-PREDICT EU Horizon2020 consortium. This study is a collaboration of 7 countries compassing 12 hospitals. The hospitals will participate in the study by recruiting patients from the respective countries and ensuring that the study includes a total of 240 patients with cirrhosis and ascites. The aim is to investigate whether a new biomarker can be used to predict which patients with cirrhosis and ascites, who will benefit most from regular human albumin infusions.
From a previous study within the MICROB-PREDICT consortium, we identified a biomarker in the blood of patients that seemed to predict response to albumin in patients with cirrhosis.
The trial that is now starting will evaluate if we can validate these findings.
Therefore, the effect of long-term administration of human albumin will be investigated in a large cohort of decompensated patients with cirrhosis and ascites, stratified by their expected treatment response to human albumin.
The goal is to identify patients who are likely to clinically benefit from the long-term treatment with human albumin, resulting in fewer complications to cirrhosis and a lower risk of death.
The results of this trial are expected to be a major step forward towards personalized treatment for these patients.
The trial is a randomized, double-blind, placebo-controlled trial, where patients will be given albumin or placebo every 10 days for 6 months in a row.
Both groups will therefore be monitored equally closely for their liver disease during the trial. The complaints that patients experience from their cirrhosis are collected and compared between the albumin and placebo groups.
The trial that is now starting will evaluate if we can validate these findings.
Therefore, the effect of long-term administration of human albumin will be investigated in a large cohort of decompensated patients with cirrhosis and ascites, stratified by their expected treatment response to human albumin.
The goal is to identify patients who are likely to clinically benefit from the long-term treatment with human albumin, resulting in fewer complications to cirrhosis and a lower risk of death.
The results of this trial are expected to be a major step forward towards personalized treatment for these patients.
The trial is a randomized, double-blind, placebo-controlled trial, where patients will be given albumin or placebo every 10 days for 6 months in a row.
Both groups will therefore be monitored equally closely for their liver disease during the trial. The complaints that patients experience from their cirrhosis are collected and compared between the albumin and placebo groups.